Cargando…

Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics

Whereas recent clinical studies report metastatic melanoma survival rates high as 30–50%, many tumors remain nonresponsive or become resistant to current therapeutic strategies. Analyses of The Cancer Genome Atlas (TCGA) skin cutaneous melanoma (SKCM) data set suggests that a significant fraction of...

Descripción completa

Detalles Bibliográficos
Autores principales: Cullum, Richard L., Lucas, Lauren M., Senfeld, Jared I., Piazza, John T., Neel, Logan T., Whig, Kanupriya, Zhai, Ling, Harris, Mackenzie H., Rael, Cristina C., Taylor, Darby C., Cook, Laura J., Kaufmann, David P., Mill, Christopher P., Jacobi, Megan A., Smith, Forrest T., Suto, Mark, Bostwick, Robert, Gupta, Ram B., David, Allan E., Riese, II, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773179/
https://www.ncbi.nlm.nih.gov/pubmed/33378376
http://dx.doi.org/10.1371/journal.pone.0243901
_version_ 1783630009031720960
author Cullum, Richard L.
Lucas, Lauren M.
Senfeld, Jared I.
Piazza, John T.
Neel, Logan T.
Whig, Kanupriya
Zhai, Ling
Harris, Mackenzie H.
Rael, Cristina C.
Taylor, Darby C.
Cook, Laura J.
Kaufmann, David P.
Mill, Christopher P.
Jacobi, Megan A.
Smith, Forrest T.
Suto, Mark
Bostwick, Robert
Gupta, Ram B.
David, Allan E.
Riese, II, David J.
author_facet Cullum, Richard L.
Lucas, Lauren M.
Senfeld, Jared I.
Piazza, John T.
Neel, Logan T.
Whig, Kanupriya
Zhai, Ling
Harris, Mackenzie H.
Rael, Cristina C.
Taylor, Darby C.
Cook, Laura J.
Kaufmann, David P.
Mill, Christopher P.
Jacobi, Megan A.
Smith, Forrest T.
Suto, Mark
Bostwick, Robert
Gupta, Ram B.
David, Allan E.
Riese, II, David J.
author_sort Cullum, Richard L.
collection PubMed
description Whereas recent clinical studies report metastatic melanoma survival rates high as 30–50%, many tumors remain nonresponsive or become resistant to current therapeutic strategies. Analyses of The Cancer Genome Atlas (TCGA) skin cutaneous melanoma (SKCM) data set suggests that a significant fraction of melanomas potentially harbor gain-of-function mutations in the gene that encodes for the ErbB4 receptor tyrosine kinase. In this work, a drug discovery strategy was developed that is based on the observation that the Q43L mutant of the naturally occurring ErbB4 agonist Neuregulin-2beta (NRG2β) functions as a partial agonist at ErbB4. NRG2β/Q43L stimulates tyrosine phosphorylation, fails to stimulate ErbB4-dependent cell proliferation, and inhibits agonist-induced ErbB4-dependent cell proliferation. Compounds that exhibit these characteristics likely function as ErbB4 partial agonists, and as such hold promise as therapies for ErbB4-dependent melanomas. Consequently, three highly sensitive and reproducible (Z’ > 0.5) screening assays were developed and deployed for the identification of small-molecule ErbB4 partial agonists. Six compounds were identified that stimulate ErbB4 phosphorylation, fail to stimulate ErbB4-dependent cell proliferation, and appear to selectively inhibit ErbB4-dependent cell proliferation. Whereas further characterization is needed to evaluate the full therapeutic potential of these molecules, this drug discovery platform establishes reliable and scalable approaches for the discovery of ErbB4 inhibitors.
format Online
Article
Text
id pubmed-7773179
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-77731792021-01-08 Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics Cullum, Richard L. Lucas, Lauren M. Senfeld, Jared I. Piazza, John T. Neel, Logan T. Whig, Kanupriya Zhai, Ling Harris, Mackenzie H. Rael, Cristina C. Taylor, Darby C. Cook, Laura J. Kaufmann, David P. Mill, Christopher P. Jacobi, Megan A. Smith, Forrest T. Suto, Mark Bostwick, Robert Gupta, Ram B. David, Allan E. Riese, II, David J. PLoS One Research Article Whereas recent clinical studies report metastatic melanoma survival rates high as 30–50%, many tumors remain nonresponsive or become resistant to current therapeutic strategies. Analyses of The Cancer Genome Atlas (TCGA) skin cutaneous melanoma (SKCM) data set suggests that a significant fraction of melanomas potentially harbor gain-of-function mutations in the gene that encodes for the ErbB4 receptor tyrosine kinase. In this work, a drug discovery strategy was developed that is based on the observation that the Q43L mutant of the naturally occurring ErbB4 agonist Neuregulin-2beta (NRG2β) functions as a partial agonist at ErbB4. NRG2β/Q43L stimulates tyrosine phosphorylation, fails to stimulate ErbB4-dependent cell proliferation, and inhibits agonist-induced ErbB4-dependent cell proliferation. Compounds that exhibit these characteristics likely function as ErbB4 partial agonists, and as such hold promise as therapies for ErbB4-dependent melanomas. Consequently, three highly sensitive and reproducible (Z’ > 0.5) screening assays were developed and deployed for the identification of small-molecule ErbB4 partial agonists. Six compounds were identified that stimulate ErbB4 phosphorylation, fail to stimulate ErbB4-dependent cell proliferation, and appear to selectively inhibit ErbB4-dependent cell proliferation. Whereas further characterization is needed to evaluate the full therapeutic potential of these molecules, this drug discovery platform establishes reliable and scalable approaches for the discovery of ErbB4 inhibitors. Public Library of Science 2020-12-30 /pmc/articles/PMC7773179/ /pubmed/33378376 http://dx.doi.org/10.1371/journal.pone.0243901 Text en © 2020 Cullum et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Cullum, Richard L.
Lucas, Lauren M.
Senfeld, Jared I.
Piazza, John T.
Neel, Logan T.
Whig, Kanupriya
Zhai, Ling
Harris, Mackenzie H.
Rael, Cristina C.
Taylor, Darby C.
Cook, Laura J.
Kaufmann, David P.
Mill, Christopher P.
Jacobi, Megan A.
Smith, Forrest T.
Suto, Mark
Bostwick, Robert
Gupta, Ram B.
David, Allan E.
Riese, II, David J.
Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics
title Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics
title_full Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics
title_fullStr Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics
title_full_unstemmed Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics
title_short Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics
title_sort development and application of high-throughput screens for the discovery of compounds that disrupt erbb4 signaling: candidate cancer therapeutics
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773179/
https://www.ncbi.nlm.nih.gov/pubmed/33378376
http://dx.doi.org/10.1371/journal.pone.0243901
work_keys_str_mv AT cullumrichardl developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics
AT lucaslaurenm developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics
AT senfeldjaredi developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics
AT piazzajohnt developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics
AT neellogant developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics
AT whigkanupriya developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics
AT zhailing developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics
AT harrismackenzieh developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics
AT raelcristinac developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics
AT taylordarbyc developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics
AT cooklauraj developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics
AT kaufmanndavidp developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics
AT millchristopherp developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics
AT jacobimegana developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics
AT smithforrestt developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics
AT sutomark developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics
AT bostwickrobert developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics
AT guptaramb developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics
AT davidallane developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics
AT rieseiidavidj developmentandapplicationofhighthroughputscreensforthediscoveryofcompoundsthatdisrupterbb4signalingcandidatecancertherapeutics